Price Chart

Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
URL http://www.abbvieinvestor.com
Investor Relations URL https://investors.abbvie.com
HQ State/Province Illinois
Sector Health Care
Industry Biotechnology
Equity Style Large Cap/Value
Next Earnings Release Jan. 31, 2025 (est.)
Last Earnings Release Oct. 30, 2024
Next Ex-Dividend Date Jan. 15, 2025
Last Ex-Dividend Date Oct. 15, 2024

Profile

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
URL http://www.abbvieinvestor.com
Investor Relations URL https://investors.abbvie.com
HQ State/Province Illinois
Sector Health Care
Industry Biotechnology
Equity Style Large Cap/Value
Next Earnings Release Jan. 31, 2025 (est.)
Last Earnings Release Oct. 30, 2024
Next Ex-Dividend Date Jan. 15, 2025
Last Ex-Dividend Date Oct. 15, 2024